Idera Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Idera Pharmaceuticals generated cash of -$24,495,000, which is more than the previous year. Cash used in financing activities reached the amount of -$1,488,000 last year. Net change in cash is therefore -$20,501,000.
Cash Flow
| 2013 | -17.13M | -9.34M | 42.65M |
|---|---|---|---|
| 2014 | -31.32M | -20.60M | 45.61M |
| 2015 | -42.98M | -33.41M | 83.01M |
| 2016 | -28.20M | 31.36M | 50.91M |
| 2017 | -55.25M | 28.06M | 59.15M |
| 2018 | -51.91M | 215K | 10.19M |
| 2019 | -44.49M | -2.40M | 15.48M |
| 2020 | -33.77M | -1.68M | 28.66M |
| 2021 | -24.59M | 4.5M | 19.41M |
| 2022 | -24.49M | 5.48M | -1.48M |
IDRA Cash Flow Statement (2013 – 2022)
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 32.54M | 33.22M | 40.01M | 71.43M | 112.94M | 80.66M | 26.58M | 19.97M | 26.27M | 10.09M |
Operating activities | ||||||||||
Net income | -23.36M | 98.09M | -112.66M | -56.51M | -59.88M | -65.98M | -38.38M | -48.55M | -38.64M | -18.22M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 15K | 22K | 61K | 120K | 432K | 746K | 656K | 488K | 206K | 137K |
Stock-based compensation expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.39M |
| Deferred income tax benefit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.39M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -2.29M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 2.54M | -1.75M | -1.62M | -1.10M | -866K | 1.67M | 1.98M | -1.70M | 2.80M | 74K |
Cash generated by operating activities | -24.49M | -24.59M | -33.77M | -44.49M | -51.91M | -55.25M | -28.20M | -42.98M | -31.32M | -17.13M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | -12.17M | -44.50M | 0 | 0 | -2.94M | -63.10M | -23.62M | -9.33M |
Investments In Property Plant And Equipment | 0 | 0 | -8K | -11K | -75K | -206K | -408K | -727K | -1.09M | -9K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 5.48M | 4.5M | -1.68M | -2.40M | 215K | 28.06M | 31.36M | -33.41M | -20.60M | -9.34M |
Financing activities | ||||||||||
Common Stock Issued | -15K | 152K | 28.75M | 15.37M | 0 | 53.76M | 49.01M | 80.59M | 37.13M | 40.20M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1.06M |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | -217K | 0 | -217K | 0 | -268K | 0 | -5K | -4K |
Cash used in financing activities | -1.48M | 19.41M | 28.66M | 15.48M | 10.19M | 59.15M | 50.91M | 83.01M | 45.61M | 42.65M |
Net Change In Cash | -20.50M | -684K | -6.79M | -31.41M | -41.50M | 31.96M | 54.08M | 6.61M | -6.30M | 16.18M |
Cash at end of period | 12.04M | 32.54M | 33.22M | 40.01M | 71.43M | 112.62M | 80.66M | 26.58M | 19.97M | 26.27M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |